[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"radiation-induced-oral-mucositis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:radiation-induced-oral-mucositis":112},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,45,76,100,127,161,193],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100616911","phase-3-prevention-and-treatment-of-radiation-induced-oral-mucositis-in-npc-with-houyanqing-oral-liquid-100616911",false,"NCT07311772","Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid","A Randomized Controlled Study of Houyanqing Oral Liquid Combined With Conventional Treatment Versus Conventional Treatment Alone for Preventing and Treating Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. Staged as Stage I-IV according to the 9th edition of the TNM Classification of Malignant Tumors formulated by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC);\n2. Age: 18 to 75 years old;\n3. Karnofsky Performance Status (KPS) score ≥ 80 before treatment;\n4. No oral diseases (such as oral mucositis or salivary gland damage) before radiotherapy;\n5. Requiring radical radiotherapy;\n6. The patient has signed the informed consent form and is willing and able to comply with the study's follow-up visits, treatment plan, laboratory tests, and other research procedures.\n\nExclusion Criteria:\n\n1. Patients with confirmed tumor recurrence, distant tumor metastasis, or who have received other anti-tumor treatments;\n2. Previous history of head and neck radiotherapy;\n3. Known allergy to the drugs used in this study (Houyanqing Oral Liquid, any conventional treatment drugs);\n4. Local use of Houyanqing Oral Liquid, Recombinant Human Epidermal Growth Factor (rhEGF) Topical Solution, Vitamin B12 Solution, or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) mouthwash in the oral cavity within one month before enrollment;\n5. Comorbidities requiring long-term treatment with immunosuppressive drugs, or systemic\u002Flocal use of corticosteroids at immunosuppressive doses before enrollment;\n6. HIV-positive patients;\n7. Pregnant women or lactating women;\n8. Patients with severe mental illnesses;\n9. Patients with severe cardio-cerebrovascular diseases, endocrine disorders, infectious diseases, or other tumors.","ALL","18 Years","75 Years",{"count":20,"type":21},386,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","To explore the efficacy of Houyanqing Oral Liquid combined with conventional treatment in preventing and treating radiation-induced oral mucositis, so as to improve the quality of life of nasopharyngeal carcinoma patients received radiotherapy.",[27,28],"Nasopharyngeal Cancinoma (NPC)","Radiation-induced Oral Mucositis",[30,28,31],"Nasopharyngeal Cancinoma","Houyanqing Oral Liquid","RECRUITING","2026-05-06",{"date":35,"type":36},"2026-05-07","ACTUAL",{"date":38,"type":36},"2025-12-16",{"date":40,"type":21},"2027-08-15",{"name":42,"class":43},"Sun Yat-sen University","OTHER",16,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100634380","a-phase-ii-prospective-open-label-randomized-multicenter-study-of-kangfu-spray-for-the-prevention-of-radiation-induced-oral-mucositis-in-patients-with-oral-malignancies-receiving-intensity-modulated-radiotherapy-100634380","NCT07538934","A Phase II Prospective, Open-Label, Randomized, Multicenter Study of Kangfu Spray for the Prevention of Radiation-Induced Oral Mucositis in Patients With Oral Malignancies Receiving Intensity-Modulated Radiotherapy","A Prospective, Open-Label, Randomized, Controlled, Multicenter Phase II Study of Kangfu Spray for the Prevention of Radiation-Induced Oral Mucositis in Patients With Oral Malignancies Undergoing Intensity-Modulated Radiotherapy","Inclusion Criteria:\n\n* Histologically confirmed oral malignancy.\n* Age 18 to 80 years.\n* Karnofsky Performance Status (KPS) score \\>=70.\n* Planned to receive definitive or postoperative adjuvant intensity-modulated radiotherapy (IMRT), with or without concurrent chemoradiotherapy, after multidisciplinary team evaluation.\n* Adequate organ function, including white blood cell count \\>=2.0 x 10\\^9\u002FL, absolute neutrophil count \\>=1.0 x 10\\^9\u002FL, platelet count \\>=80 x 10\\^9\u002FL, hemoglobin \\>=90 g\u002FL, serum creatinine \\\u003C=1.5 x upper limit of normal (ULN) or creatinine clearance \\>=50 mL\u002Fmin, total bilirubin \\\u003C=1.5 x ULN, and AST\u002FALT \\\u003C=2.5 x ULN.\n* Able to understand and comply with study procedures.\n* Written informed consent provided.\n\nExclusion Criteria:\n\n* Known allergy to Kangfu Spray or severe allergic predisposition.\n* Uncontrolled immune-related oral mucosal disease or prior related immune mucosal disease.\n* Pregnancy or breastfeeding.\n* Prior radiotherapy to the head and neck region.\n* Any severe concomitant disease or condition that, in the investigator's judgment, makes the participant unsuitable for participation.","80 Years",{"count":54,"type":21},140,[56],"NA","This is a prospective, open-label, randomized, controlled, multicenter phase II study evaluating the efficacy and safety of Kangfu Spray for the prevention of radiation-induced oral mucositis in patients with histologically confirmed oral malignancies receiving intensity-modulated radiotherapy (IMRT), with or without concurrent platinum-based chemotherapy.\n\nEligible participants will undergo definitive or postoperative adjuvant IMRT according to multidisciplinary team recommendations. Participants in the experimental group will receive Kangfu Spray prophylactically from the first day of radiotherapy until completion of radiotherapy, in addition to standard oral care. The primary endpoint is the incidence of severe radiation-induced oral mucositis, defined as World Health Organization (WHO) grade 3 or higher. Secondary endpoints include time to onset and duration of severe oral mucositis, incidence and duration of any oral mucositis, oral ulcer and pain scores, radiotherapy interruption, opioid analgesic use, nutritional indicators, quality of life, and safety. Exploratory analyses will evaluate lymphocytes, inflammatory factors, and microbiota in blood and saliva.",[28,59],"Oral Malignancy",[61,62,63,64,65],"Kangfu Spray","radiation-induced oral mucositis","oral cancer","chemoradiotherapy","oral mucositis prevention","NOT_YET_RECRUITING","2026-04-13",{"date":69,"type":36},"2026-04-20",{"date":71,"type":21},"2026-07-01",{"date":73,"type":21},"2029-10-01",{"name":75,"class":43},"YE ZHANG",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":99},"100614660","phase-2-traditional-chinese-medicine-oral-liquids-and-mouthwashes-for-radiation-induced-oral-mucositis-in-head-and-neck-cancer-patients-100614660","NCT07282483","Traditional Chinese Medicine Oral Liquids and Mouthwashes for Radiation-induced Oral Mucositis in Head and Neck Cancer Patients","Traditional Chinese Medicine Oral Liquids and Mouthwashes for Radiation-induced Oral Mucositis in Head and Neck Cancer Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients pathologically diagnosed with non-metastatic head and neck malignant tumors;\n2. Age range: 18 to 65 years old (including 18 and 65 years old);\n3. Eastern Cooperative Oncology Group performance status of ≤2;\n4. Radiotherapy or concurrent chemoradiotherapy is required;\n5. The main organ functions well;\n6. Sign informed consent.\n\nExclusion Criteria:\n\n1. Allergic constitution (such as those known to be allergic to two or more drugs);\n2. Patients who plan to use drugs that can cause or worsen oral mucosal inflammation (such as anti EGFR monoclonal antibodies, immune checkpoint inhibitors, etc.) after the start of radiotherapy;\n3. Use of antibiotics, antifungal drugs, or antimicrobial mouthwash within 1 month of the study;\n4. Poor oral hygiene and\u002For severe periodontal diseases;\n5. History of head and neck radiotherapy;\n6. Deemed unsuitable for the study by the investigators (concomitant with any other severe diseases).","65 Years",{"count":85,"type":21},118,[87],"PHASE2","Evaluate the efficacy and safety of traditional Chinese medicine oral liquid and mouthwash in the treatment of radiotherapy induced oral mucositis in patients with head and neck malignancies",[28],"2026-03-21",{"date":92,"type":36},"2026-03-25",{"date":94,"type":36},"2026-03-16",{"date":96,"type":21},"2026-10-31",{"name":98,"class":43},"West China Hospital",1,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":114,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":99},"100595186","phase-2-taurines-therapeutic-effect-on-acute-radiation-induced-oral-mucositis-and-dermatitis-100595186","NCT07029178","Taurine's Therapeutic Effect on Acute Radiation-induced Oral Mucositis and Dermatitis","A Randomized Controlled Trial on Taurine's Therapeutic Effect on Acute Radiation-induced Oral Mucositis and Dermatitis","Inclusion Criteria:\n\n1. Patients voluntarily joined the study, were informed of the purpose and process of the study, signed the informed consent form, and were willing and able to abide by the study protocol.\n2. Aged 18 to 80, with no gender restrictions.\n3. Patients that require radiotherapy after surgery for oral\u002Foropharyngeal cancer. After evaluation by the radiation oncologist, radiotherapy at 30 sessions \u002F60Gy is planned.\n4. The expected survival period is more than 6 months.\n5. No radiotherapy for the head and neck has been performed in the past, and no other medications that affect the results of this trial have been used. No chemotherapy or immunotherapy was performed within one month before the beginning of the trial.\n\nExclusion criteria:\n\n1. Uncontrollable local or systemic infections of the oral cavity and head and neck.\n2. Active or history of autoimmune diseases; Diseases requiring systemic steroid hormones or immunosuppressive medications.\n3. Bleeding occurred within 3 months before enrollment, including but not limited to: gastrointestinal bleeding caused by gastric fundus or esophageal varices, increased risk of bleeding caused by portal hypertension, active gastrointestinal bleeding, etc. Or there is a risk of major bleeding as assessed by the researcher.\n4. Arterial\u002Fvenous thrombosis that occurred within 6 months prior to the screening, such as cerebrovascular accidents, deep vein thrombosis and pulmonary embolism, etc.\n5. Interstitial pneumonia or active pneumonia with clinical significance, or other respiratory diseases that seriously affect lung function.\n6. History of cardiovascular diseases, including but not limited to: (1) Congestive heart failure (NYHA grade \\> 2); (2) Unstable angina pectoris; (3) Myocardial infarction occurred in the past three months; (4) Any supraventricular arrhythmia or ventricular arrhythmia that requires treatment or intervention.\n7. Severe endocrine or hematopoietic system diseases (such as diabetes, leukemia, etc.), gastrointestinal obstruction, active bleeding, gastric perforation and other conditions.\n8. Combined with malignant tumors of other organs.\n9. Intractable or refractory epilepsy, with a large amount of pleural effusion, ascites, pericardial effusion, etc. that cannot be controlled by medicines.\n10. History of HIV, syphilis, active hepatitis, active pulmonary tuberculosis, active EBV and\u002For CMV infection within one year before screening, or those with a history of active pulmonary tuberculosis infection for more than one year without regular treatment; active hepatitis B or C. Patients with positive HBsAg or HBcAb can participate in this study if the HBV DNA test is below the lower limit of the normal value detected by the research center; patients with positive HCV antibody can participate in this study if the HCV RNA test is below the lower limit of the normal value detected by the research center.\n11. History of allogeneic bone marrow transplantation or solid organ transplantation.\n12. Have received cell therapy products that have undergone genetic modification or editing in the past.\n13. Have previously used medicines that can cause medication-related osteonecrosis of the jaw.\n14. Have taken drugs containing taurine within one month before randomization in this study.\n15. Allergic to taurine.\n16. Patients who, in addition to radiotherapy, requires chemotherapy or immunotherapy simultaneously.\n17. Mental illness, alcohol abuser, drug user or drug abuser.\n18. Pregnant or lactating women; Women who plans to become pregnant within half a year after treatment.\n19. Poor compliance or other circumstances assessed by the researcher as unsuitable for participation in this clinical study.",{"count":108,"type":21},160,[87],"This is a single-center, double-blind, randomized controlled study. The patients were divided into control group and experimental group, 80 cases each. From the first day of radiotherapy to the end of radiotherapy, the experimental group was treated with 24 grams of taurine granule (containing 4.8 grams of taurine) before each day's radiotherapy. The control group was treated with the same amount of placebo.",[112,113],"Radiation Induced Oral Mucositis","Radiodermatitis",[115,116,117,118,62],"double-blind","randomized controlled trial","taurine","radiodermatitis",{"date":120,"type":36},"2026-03-18",{"date":122,"type":36},"2025-11-24",{"date":124,"type":21},"2027-12-31",{"name":126,"class":43},"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":135,"maxAge":52,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":139,"conditions":140,"keywords":145,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":99},"100612359","mouthwash-temperature-and-oral-mucositis-in-head-and-neck-radiotherapy-100612359","NCT07252557","Mouthwash Temperature and Oral Mucositis in Head and Neck Radiotherapy","Effectiveness of Different Mouthwash Temperatures on Oral Mucositis Pain and Patient Comfort During Radiotherapy for Head and Neck Cancer: A Randomized Controlled Trial","CoolRinseHNC","Inclusion Criteria:\n\n* Histologically confirmed head and neck cancer (HNC) receiving radiotherapy for the first time, with or without concurrent chemotherapy.\n* Conscious, communicative, and able to perform the rinsing procedure and complete questionnaires.\n* Provided written informed consent prior to enrollment.\n\nExclusion Criteria:\n\n* Non-HNC diagnoses or radiotherapy to sites outside the oral\u002Foropharyngeal region.\n* Cognitive impairment or inability to complete the rinsing protocol.","20 Years",{"count":137,"type":21},200,[56],"This single-center randomized controlled trial evaluates the effects of cold (15-20°C) versus room-temperature (30-35°C) water gargling on oral mucositis severity, pain, and comfort in patients with head and neck cancer undergoing radiotherapy. Participants will rinse their mouth four times daily for 30-60 seconds over a 6-week radiotherapy course, with follow-up for two additional weeks. The study hypothesizes that cold-water rinsing can reduce the severity of radiation-induced oral mucositis (RTOM) and pain, improve oral comfort, and minimize treatment interruptions.",[141,28,142,143,144],"Head and Neck Cancer (H&Amp;Amp;N)","Supportive Care","Nursing Interventions","Radiotherapy Side Effects",[146,147,148,149,142,150,151,152],"Head and Neck Cancer","Radiation-Induced Oral Mucositis","Water Temperature","Cold Water Rinse","Pain Management","Radiotherapy","Nursing Intervention",{"date":154,"type":36},"2025-11-26",{"date":156,"type":21},"2026-01-01",{"date":158,"type":21},"2027-03-31",{"name":160,"class":43},"Chung Shan Medical University",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":22,"phases":171,"briefSummary":172,"conditions":173,"keywords":176,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":99},"100611613","rice-bran-supplementation-for-radiation-induced-oral-mucositis-in-head-and-neck-cancer-100611613","NCT07242859","Rice Bran Supplementation for Radiation-Induced Oral Mucositis in Head and Neck Cancer","Effects of Rice Bran on Radiation-Induced Oral Mucositis in Patients With Head\u002FNeck Cancer and Its Impact on the Quality of Life","RICE-MUC","Inclusion Criteria:\n\n* Male or female patients of age 18 years old tor more\n* Patients with squamous cell carcinomas without metastases of other non-head and non-neck tumors.\n* Patients undergoing radiotherapy with an ECOG performance status of 0, 1, or 2\n* Patients who will receive IMRT delivered as radical or adjuvant therapy with or without concurrent chemotherapy\n* Ready to provide written informed consent\n\nExclusion Criteria:\n\n* Receiving any other approved or investigational anti-cancer agent than those specified in this study.\n* Pregnant or breastfeeding female patients\n* Patients who have oral lesions unrelated to treatment or cancer,\n* Patients who are on drugs that could cause oral lesions or are using anticoagulants.",{"count":170,"type":21},80,[56],"This study aims to find out if taking rice bran supplements can help reduce the painful mouth sores (oral mucositis) that often occur in patients with head and neck cancer who receive radiation therapy. The trial will include adult patients undergoing radiation treatment. Participants will be given rice bran supplements during their therapy to see if it can lessen these side effects and improve their overall quality of life.",[147,174,175],"Head &Amp; Neck Cancer","Head &Amp; Neck Squamous Cell Carcinoma",[147,177,146,178,179,180,181,142,182,183],"Oral Mucositis","Rice Bran","Dietary Supplement","Radiation Therapy Side Effects","Quality of Life","Antioxidants","Cancer Treatment Support","2025-11-17",{"date":186,"type":36},"2025-11-21",{"date":188,"type":36},"2023-01-15",{"date":190,"type":21},"2025-12-30",{"name":192,"class":43},"Christina Milad Lobos",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":201,"targetDuration":4,"studyType":22,"phases":203,"briefSummary":205,"conditions":206,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":99},"100588298","phase-1-hydroxychloroquine-sulfate-tablets-for-radiation-induced-oral-mucositis-100588298","NCT06939582","Hydroxychloroquine Sulfate Tablets for Radiation-induced Oral Mucositis","A Single Center, Open Label Phase II Clinical Trial of Hydroxychloroquine Sulfate Tablets for the Treatment of Radiation Stomatitis and Taste Disturbance in Intensity Modulated Radiotherapy for Head and Neck Cancer","RIOM","Inclusion Criteria:\n\n* Patients pathologically diagnosed with non-metastatic head and neck malignant tumors\n* Aged 18-80 years\n* Eastern Cooperative Oncology Group performance status of ≤2\n* Planning to receive definitive RT or postoperative adjuvant RT\n* Normal liver, kidney and bone marrow function\n* Sign informed consent\n\nExclusion Criteria:\n\n* Those who are known to be allergic to 4-aminoquinoline compounds or have more serious allergic constitution\n* Had a history of head and neck radiotherapy\n* Patients with non head and neck parts in the radiotherapy area\n* Poor oral hygiene or severe periodontitis\n* Suffering from severe kidney disease, severe cardiovascular disease, myasthenia gravis, Parkinson's disease or epilepsy\n* Recently taking or taking diuretics or other drugs known to interact with hydroxychloroquine sulfate tablets\n* Retinopathy\n* Other patients (combined with any serious other diseases) who the investigator believes are not suitable for participation in this study",{"count":202,"type":21},158,[204,87],"PHASE1","Evaluate the safety, tolerance and efficacy of hydroxychloroquine sulfate tablets the prevention and treatment of oral mucositis and dysgeusia in patients undergoing radiotherapy",[28],"2025-04-26",{"date":209,"type":36},"2025-04-29",{"date":211,"type":36},"2024-12-22",{"date":213,"type":21},"2025-06-20",{"name":215,"class":43},"Xingchen Peng"]